newsfilter
← Latest News
GlobeNewswire·

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND